test

An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Conditions

Esophagus | Other Digestive Organ

What is the purpose of this trial?

To demonstrate the antitumor activity as assessed by the rate of progression free survival at three months of the sanofi-aventis product cabazitaxel 25mg/m2 IV over 1 hour every 3 weeks in subjects with previously treated metastatic gastroesophageal adenocarcinoma who are either taxane naïve, or taxane previously treated

Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Weill Medical College of Cornell University
Dates:
07/22/2014
Last Updated:
Study HIC#:
1312013191